Methoxetamine: An early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample

Drug and Alcohol Review

Volumn 35, Issue 2, 2016, Pages 212-217

  Winstock, Adam R ^a,b,c   Lawn, Will ^d   Deluca, Paolo ^b   Borschmann, Rohan ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Global Drug Survey   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Ketamine; Methoxetamine; Monitoring system; Novel psychoactive substance

Indexed keywords

2-(3-METHOXYPHENYL)-2-(ETHYLAMINO)CYCLOHEXANONE; CYCLOHEXANONE DERIVATIVE; CYCLOHEXYLAMINE DERIVATIVE; KETAMINE; PSYCHEDELIC AGENT; STREET DRUG;

ADULT; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MOTIVATION; PREVALENCE; QUESTIONNAIRE; SUBSTANCE-RELATED DISORDERS; UNITED KINGDOM; YOUNG ADULT;

ADULT; CROSS-SECTIONAL STUDIES; CYCLOHEXANONES; CYCLOHEXYLAMINES; FEMALE; HALLUCINOGENS; HUMANS; KETAMINE; MALE; MOTIVATION; PREVALENCE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES; UNITED KINGDOM; YOUNG ADULT;

EID: 84927633182     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12259     Document Type: Article

References (35)

1. Morris H. Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist. Vice Magazine, 2011.
2. UK Government (2012). Offence Recording Codes. Available at: http://www.homeoffice.gov.uk/about-us/corporate-publications-strategy/home-office-circulars/circulars-2012/008-2012/ (accessed 3 March 2015).
3. Advisory Council on the Misuse of Drugs (ACMD). Methoxetamine Report. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119087/methoxetamine2012.pdf (accessed January 2014).
4. Erowid. Documenting the Complex Relationship between Humans and Psychoactives. Available at: http://www.erowid.org (accessed April 2012).
5. Google. Google Insights for Search: Methoxetamine [Internet]. Google Insights for Search. Available at: http://www.google.com/insights/search/#q=methoxetamine&cmpt=q (accessed February 2014).
6. Roth BL, Gibbons S, Arunotayanun W, etal. The ketamine analogue methoxetamine and 3-and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE 2013;8:1-5.
7. Gibbons S. 'Legal highs'-novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin Toxicol 2012;50:15-24.
8. Rosenbum CD, Carreiro SP, Babu KM. Here today, gone tomorrow ... and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), Kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012;8:15-32. doi: 10.1007/s13181-011-0202-2. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22271566.
9. Ward J, Rhyee S, Plansky J, Boyer E. Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol 2011;49:874-875.
10. Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol 2012;68:853-856. doi: 10.1007/s00228-011-1199-9. Epub 2011 Dec 29. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22205276 (accessed 29 December).
11. Hofer KE, Grager B, Muller DM, etal. Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med 2012;60:97-99. doi: 10.1016/j.annemergmed.2011.11.018. Epub 2012 Jan 10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22237166 (accessed 10 January).
12. Kjellgren A, Jonsson K. Methoxetamine (MXE)-a phenomenological study of experiences induced by a 'legal high' available from the Internet. J Psychoactive Drugs 2013;47:276-286.
13. Corazza O, Schifano F, Simonato P, etal. The phenomenon of new drugs on the Internet: a study on the diffusion of the ketamine derivative methoxetamine ('MXE'). Hum Psychopharmacol 2012;27:145-149.
14. Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol 2012a;68:853-856.
15. Wood DM, Hunter L, Measham F, Dargan PI. Limited use of novel psychoactive substances in South London nightclubs. QJM 2012b;105:959-964.
16. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001;64:9-17.
17. Winstock AR, Mitcheson LR, Deluca P, Schifano F, Davey Z, Corazza O. Mephedrone new kid for the chop? Addiction 2011a;106:154-161.
18. Winstock AR, Mitcheson L, Gillatt DA, Cottrell A. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int 2012;110:1762-1766. March 14 online.
19. McCambridge J, Mitcheson L, Winstock AR, Hunt N. Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom. Addiction 2005;100:1140-1149.
20. Winstock A, Marsden J. 'Mephedrone: assessment of health risks and harms', Appendix 1 to the: risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone), EMCDDA contract: CT.10.EPI.034, 2010.
21. Winstock AR, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone-subjects effects, health and abuse liability. Addiction 2011b;106:1991-1996.
22. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007;69:810-812.
23. Chu PSK, Ma WK, Wong SCW, etal. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 2008;102:1616-1622.
24. Yeung LY, Rudd JA, Lam WP, Mak YT, Yew DT. Mice are prone to kidney pathology after prolonged ketamine addiction. Toxicol Lett 2009;191:275-278.
25. Dargan PI, Tang HC, Liang W, Wood DM, Yew DT. Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin Toxicol 2014;52:176-180.
26. Lawn W, Borschmann R, Cottrell A, Winstock AR. Methoxetamine: prevalence of use in the USA and UK and associated urinary problems. J Psychoactive Drugs 2014;In press.
27. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010;105:121-133.
28. Morgan CJ, Curran HV. Ketamine use: a review. Addiction 2012;107:27-38.
29. Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS. Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol 2012;50:438-440.
30. Winstock AR, Marsden J, Mitcheson L. What should be done about mephedrone. BMJ 2010;340:c1605.
31. Winstock AR, Ramsey JD. Legal highs and the challenges for policy makers. Addiction 2010;105:1685-1687.
32. Winstock AR, Wilkins C 'Legal highs' The challenge of new psychoactive substances Series on Legislative Reform of Drug Policies Nr. 16 October 2011 IDPC and TNI, 2011.
33. Moore K, Dargan PI, Wood DM, Measham F. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. Eur Addict Res 2013;19:276-282.
34. Topp L, Breen C, Kaye S, Darke S. Adapting the illicit drug reporting system (IDRS) to examine the feasibility of monitoring trends in the markets for 'party drugs'. Drug Alcohol Depend 2004;73:189-197.
35. Winstock AR, Wolff K, Ramsey J. 4 MTA a new synthetic drug on the dance scene. Drug Alcohol Depend 2002;67:111-115.